• 대한영상의학회지
• /
• 제79권6호
• /
• pp.303-310
• /
• 2018

목적: 이 연구의 목적은 흉부 전산화단층촬영(CT)에서 우연히 발견된 유방 병변의 임상적 중요성을 평가하고 유방 전문 진료 의뢰가 필요한 영상 소견을 제안하는 것이다. 대상과 방법: 2009년 5월부터 2014년 4월까지 촬영된 조영증강 흉부 CT 중에서 판독문에 '유방'이라는 단어가 포함된 검사를 후향적으로 검토하였다. 이 중 우연히 발견된 유방 병변으로 유방 초음파와 유방 촬영술을 한 뒤, 병리학적 확인이나 1년 이상의 추적 관찰을 받은 총 86명의 환자(모두 여성, 평균 연령, $48.9{\pm}12.6$세)를 대상으로 하였다. 흉부 CT에서 유방 병변의 크기, 위치, 모양, 경계 및 조영 증강을 포함한 영상 특징을 평가하였다. 다양한 CT 특징과 병리소견과의 연관성을 평가하고 여러 조합의 CT 특징의 진단 정확도를 평가하였다. 결과: 흉부 CT에서 우연히 발견된 유방 병변 중 악성 종양은 16.3%(14/86)였다. 악성 병변은 양성 병변에 비해 불규칙한 모양, 불분명한 경계, 높은 조영증강을 보였다. CT 특징의 조합 중 불분명한 경계와 높은 조영증강의 조합이 악성 병변을 예측하는데 가장 높은 정확도를 보였다(97.7%). 결론: 흉부 CT에서 우연히 발견된 유방 병변의 16.3%는 악성이었으며, 불분명한 경계와 높은 조영증강을 동시에 보일 경우 악성 가능성이 높으므로, 정확한 진단을 위해 유방 전문 진료 의뢰가 필요하다.

• 대한기관식도과학회지
• /
• 제7권2호
• /
• pp.168-173
• /
• 2001

Background and Objectives： The introduction of highly sensitive imaging techniques has made it possible to detect many non-palpable nodules, or“incidentaloma”in the thyroid. Discovery of these lesions raises concerns about their malignancy, but the optimal strategy for managing these lesions has not been clearly established. This study was designed to evaluate the usefulness of ultrasonographic exam with new diagnostic criteria and presume the value of mass screening for thyroid cancer. Materials and Methods : Mass screening for thyroid cancer were carried out in conjunction with mass screening for breast cancer. The subjects were 630 women aged 30 years or over. Thyroid glands were examined with 10 MHz transducer ultrasonography by one radiologist. Needle aspiration biopsy were performed when suspicious of malignancy under the new diagnostic criteria. Results and Conclusion : The new ultrasonographic criteria to diagnose thyroid cancer provided useful information and ensured more accurate evaluation. 7 cases of thyroid cancer were discovered and successfully managed. It should be further demonstrated that there is sufficient value of mass screening for thyroid cancer to perform it independently despite early cancer detection.

• Archives of Plastic Surgery
• /
• 제42권5호
• /
• pp.630-634
• /
• 2015

Pseudoangiomatous stromal hyperplasia (PASH) of the breast is a benign mesenchymal lesion with incidental histologic findings. Surgical excision is recommended as the treatment of choice for PASH, although the recurrence rates after excision range from 15% to 22%. A 46-year-old-female presented with a six-month history of bilateral breast enlargement and painful sensation mimicking inflammatory carcinoma. Imaging studies demonstrated innumerable enhancing nodules in both breasts. Due to the growth of the lesions and progressive clinical symptoms, bilateral subcutaneous mastectomy was performed. Grossly, the specimens were round and well-circumscribed, and the histologic examination revealed PASH. After mastectomy, we created a pocket with the pectoralis major muscle and a lower skin flap, which was deepithelized. Anatomical mammary implants were inserted, and the nipple areolar complex was transferred to a new position as a free graft. The aesthetic result was satisfactory after twelve months of follow-up.

• 대한세포병리학회지
• /
• 제16권1호
• /
• pp.25-30
• /
• 2005

Pseudoangiomatous stromal hyperplasia (PASH) was initially described by Vuitch et al. as a benign breast lesion, consisting of mammary stromal proliferations which simulate vascular lesions, and which might be mistaken for a low-grade angiosarcoma. This condition occasionally presents as a palpable mass in postmenopausal women, but is more frequently encountered as an incidental component in premenopausal women. Clinical, radiological, and fine-needle aspiration (FNA) findings associated with this condition can mimic those observed in conjunction with a phyllodes tumor or a fibroadenoma. The cytological features of PASH are generally nonspecific, and its diagnosis by FNA cytology is fairly difficult. In this study, we report a case on PASH, manifesting as a palpable mass.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권20호
• /
• pp.8699-8703
• /
• 2014

18-fluoro-2-deoxyglucose positron emission tomography-computed tomography ($^{18}F$-FDG PET/CT) scans are commonly used for the staging and restaging of various malignancies, such as head and neck, breast, colorectal and gynecological cancers. However, the value of FDG PET/CT for detecting prostate cancer is unknown. The aim of this study was to evaluate the clinical value of incidental prostate $^{18}F$-FDG uptake on PET/CT scans. We reviewed $^{18}F$-FDG PET/CT scan reports from September 2009 to September 2013, and selected cases that reported focal/diffuse FDG uptake in the prostate. We analyzed the correlation between $^{18}F$-FDG PET/CT scan findings and data collected during evaluations such as serum prostate-specific antigen (PSA) levels, digital rectal examination (DRE), transrectal ultrasound (TRUS), and/or biopsy to confirm prostate cancer. Of a total of 18,393 cases, 106 (0.6%) exhibited abnormal hypermetabolism in the prostate. Additional evaluations were performed in 66 patients. Serum PSA levels were not significantly correlated with maximum standardized uptake values (SUVmax) in all patients (rho 0.483, p=0.132). Prostate biopsies were performed in 15 patients, and prostate cancer was confirmed in 11. The median serum PSA level was 4.8 (0.55-7.06) ng/mL and 127.4 (1.06-495) ng/mL in the benign and prostate cancer groups, respectively. The median SUVmax was higher in the prostate cancer group (mean 10.1, range 3.8-24.5) than in the benign group (mean 4.3, range 3.1-8.8), but the difference was not statistically significant (p=0.078). There was no significant correlation between SUVmax and serum PSA, prostatic volume, or Gleason score. $^{18}F$-FDG PET/CT scans did not reliably differentiate malignant or benign from abnormal uptake lesions in the prostate, and routine prostate biopsy was not usually recommended in patients with abnormal FDG uptake. Nevertheless, patients with incidental prostate uptake on $^{18}F$-FDG PET/CT scans should not be ignored and should be undergo further clinical evaluations, such as PSA and DRE.